We worry about the jurisdictional creep that has been going on where you seek to grab as much regulatory territory as possible.
Look, no physician wants to tell a patient that they cannot receive the care they need because there is no treatment but because the product...
Statement, dated February 9, 2012, of American Academy of Pediatrics, submitted by Mr. Pitts.
Statement, dated February 9, 2012, of American Society of Health-System Pharmacists, submitted by Mr. Pitts.
This is the kind of issue that can and should be tackled on a bipartisan basis.
Statement, dated February 9, 2012, of National Community Pharmacists Association, submitted by Mr. Pitts.
Statement, dated February 7, 2012, of the Biotechnology Industry Organization, submitted by Mr. Pitts.
I would ask or suggest that you look into resolving this issue by considering releasing the remaining units of Primatene Mist.
A lot of folks where I come from, they can't afford a $50 substitute for a $20 product that they have been taking for way too many years.
the strong risk aversion at the FDA is creating at least the perception that it is slowing down or stopping the approval of new, innovative ...
Today, we will discuss reauthorizations of the Prescription Drug User Fee Act, PDUFA, the Best Pharmaceuticals for Children Act, BPCA, and t...